Iveric Bio Inc
F:O2T
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Iveric Bio Inc
F:O2T
|
US |
|
Rohto Pharmaceutical Co Ltd
TSE:4527
|
JP |
|
Indbank Merchant Banking Services Ltd
NSE:INDBANK
|
IN |
|
S
|
Sankyo Tateyama Inc
TSE:5932
|
JP |
|
A
|
Anbang Save-Guard Group Co Ltd
SSE:603373
|
CN |
|
Fortune Minerals Ltd
TSX:FT
|
CA |
|
Media Chinese International Ltd
HKEX:685
|
HK |
|
Jiangsu Guoxin Corp Ltd
SZSE:002608
|
CN |
|
Harvest Minerals Ltd
LSE:HMI
|
AU |
|
M
|
Mega Corp Ltd
BSE:531417
|
IN |
|
Y
|
YC Corp
KOSDAQ:232140
|
KR |
|
GFL Ltd
NSE:GFLLIMITED
|
IN |
|
Hibino Corp
TSE:2469
|
JP |
|
Saksoft Ltd
NSE:SAKSOFT
|
IN |
|
Nfon AG
XETRA:NFN
|
DE |
|
HELMA Eigenheimbau AG
XETRA:H5E
|
DE |
|
Mawson Infrastructure Group Inc
NASDAQ:MIGI
|
AU |
|
S
|
Structural Monitoring Systems PLC
ASX:SMN
|
AU |
|
Nuix Ltd
ASX:NXL
|
AU |
|
L
|
Licogi 14 JSC
VN:L14
|
VN |
|
Gosun Holding Co Ltd
SZSE:000971
|
CN |
|
M
|
MiCo Ltd
KOSDAQ:059090
|
KR |
|
Canaccord Genuity Group Inc
TSX:CF
|
CA |
|
Nikola Corp
NASDAQ:NKLA
|
US |
Iveric Bio Inc
IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 37 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). The company is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The firm is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.
IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 37 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). The company is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The firm is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
